Abstract 322P
Background
There is limited evidence regarding the prognostic value of the three-tier chemotherapy response score (CRS) in advanced epithelial ovarian cancer (EOC). We aimed to evaluate the impact of CRS on survival in advanced EOC.
Methods
This prospective single-centre study included consecutive women with stage IIIC-IV EOC who underwent interval debulking surgery (IDS) after neoadjuvant chemotherapy (NACT) at Tata Medical Center between March 2021 and June 2022. Clinical characteristics, progression-free survival (PFS), and overall survival (OS) were compared between the CRS groups.
Results
Among the 102 women treated with NACT followed by IDS, CRS 1 was found in 16 (15.7%), CRS 2 in 66 (64.7%), and CRS 3 in 20 (19.6%). Age, stage, and BRCA status were not different across CRS groups. The patients with CRS 3 had significantly longer PFS than the other CRS groups (median PFS 17 months, 19.8 months, and not reached for CRS 1, 2, and 3, respectively, P = 0.001). Estimated OS was also significantly longer in those with CRS 3 (median OS 22.2 months, 33 months, and not reached for CRS 1, 2, and 3, respectively, P = 0.035). The PFS and OS differences remained statistically significant in univariate and multivariate analyses.
Conclusions
Chemotherapy response score 3 was associated with improved survival in advanced EOC treated with NACT. The prognostic value of CRS can be used in future studies of response-adapted adjuvant or maintenance treatment in advanced EOC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
101P - The coexistence of TP53 gain-of-function mutation and hypermethylation as a poor prognostic factor in BRAF wild-type metastatic colorectal cancer
Presenter: Kota Ouchi
Session: Poster Display
Resources:
Abstract
102P - Enhancing colorectal cancer prevention in high-risk populations through faecal immunochemical test surveillance
Presenter: Li Xie
Session: Poster Display
Resources:
Abstract
103P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
104P - The value of functional MR-imaging signature model for early prediction of chemotherapy response and its guidance for regimen adjustment to improve efficacy
Presenter: Wenhua Li
Session: Poster Display
Resources:
Abstract
105P - A single-arm, phase II, multicenter study of iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors
Presenter: Weijian Guo
Session: Poster Display
Resources:
Abstract
106P - Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Updated results from a pooled analysis of two phase I studies
Presenter: Ying Yuan
Session: Poster Display
Resources:
Abstract
107P - Tumor-stromal ratio in a new age fibroblast activated protein PET imaging as a biomarker for prediction of response to neoadjuvant chemoradiotherapy in carcinoma rectum
Presenter: swetha Suresh
Session: Poster Display
Resources:
Abstract
108P - Detection of HER2 overexpression in colorectal cancer: Comparison of a HANDLE classic NGS panel with standard IHC/FISH
Presenter: Lijuan Luan
Session: Poster Display
Resources:
Abstract
109P - Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular status
Presenter: Andrea Pretta
Session: Poster Display
Resources:
Abstract
110P - The correlation between multi-dimensional characteristics of circulating tumor cells (CTC) and treatment response in patients with initially unresectable metastatic colorectal cancer
Presenter: Yu Liu
Session: Poster Display
Resources:
Abstract